Clinical Trials Directory

Trials / Completed

CompletedNCT04299412

Diagnostic Accuracy of the DPP II Assay

Diagnostic Accuracy of the DPP Fever Panel II Asia and the DPP Micro Reader

Status
Completed
Phase
Study type
Observational
Enrollment
104 (actual)
Sponsor
Foundation for Innovative New Diagnostics, Switzerland · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Burkholderia pseudomallei is responsible for melioidosis, a disease that can present a range of signs and symptoms and can be treated by a specific drug regimen. Diagnosis of melioidosis is made by isolation of the bacteria from body fluids or tissues such as blood, skin or sputum. Although this is considered the gold standard, bacterial isolation has low diagnostic sensitivity, requires specific infrastructures (biosafety level 3 laboratories) and skilled staff that are not always available in LMICs. This may lead to inappropriate patient management and care. Chembio, in partnership with FIND, has developed a multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect antigens from common causes of febrile illnesses, included Burkholderia. FIND will conduct a laboratory study in Menzies Health School of Research to estimate the diagnostic accuracy of the DPP II Assay using retrospective samples that are positive for B. pseudomallei. Results will help in estimating the diagnostic accuracy of the assay for this pathogen.

Conditions

Interventions

TypeNameDescription
DEVICEDPP Fever Panel II assayMultiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect (i) antigens produced by Dengue, Zika, Chikungunya, Malaria and Burkholderia and (ii) IgM directed against Dengue, Zika, Chikungunya, Leptospira, Rickettsia typhi and Orientia tsutsugamushi. The assay comes with a reader that provides results interpretation to the operator in a few seconds

Timeline

Start date
2019-10-28
Primary completion
2020-07-30
Completion
2020-09-30
First posted
2020-03-06
Last updated
2023-11-30

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT04299412. Inclusion in this directory is not an endorsement.